Mesenchymal stem cells are injured by complement after their contact with serum
about
Mesenchymal Stem Cells after Polytrauma: Actor and TargetComplement activation in the context of stem cells and tissue repairMesenchymal stem cells as a vector for the inflammatory prostate microenvironmentMesenchymal stem cells: immune evasive, not immune privilegedOptimization of pre-transplantation conditions to enhance the efficacy of mesenchymal stem cellsAdult Stem Cell Therapy for Stroke: Challenges and ProgressGenetically modified mesenchymal stromal cells in cancer therapyInternational Society for Cellular Therapy perspective on immune functional assays for mesenchymal stromal cells as potency release criterion for advanced phase clinical trials.Dynamic Imaging of Marrow-Resident Granulocytes Interacting with Human Mesenchymal Stem Cells upon Systemic Lipopolysaccharide Challenge.MHC-matched induced pluripotent stem cells can attenuate cellular and humoral immune responses but are still susceptible to innate immunity in pigsMesenchymal stem cells engineered to inhibit complement-mediated damage.Changes in immunological profile of allogeneic mesenchymal stem cells after differentiation: should we be concerned?Treatment of severe chronic graft-versus-host disease with decidual stromal cells and tracing with (111)indium radiolabeling.Human mesenchymal stromal cells attenuate graft-versus-host disease and maintain graft-versus-leukemia activity following experimental allogeneic bone marrow transplantation.In vitro augmentation of mesenchymal stem cells viability in stressful microenvironments : In vitro augmentation of mesenchymal stem cells viabilityThe TLR7 agonist Imiquimod promote the immunogenicity of mesenchymal stem cells.Do cryopreserved mesenchymal stromal cells display impaired immunomodulatory and therapeutic properties?Human bone marrow stromal cell confluence: effects on cell characteristics and methods of assessment.Presence of retinal pericyte-reactive autoantibodies in diabetic retinopathy patients.Safety of Intraperitoneal Injection of Adipose Tissue-Derived Autologous Mesenchymal Stem Cells in Cats.Target deletion of complement component 9 attenuates antibody-mediated hemolysis and lipopolysaccharide (LPS)-induced acute shock in mice.Mesenchymal Stem Cells Reversed Morphine Tolerance and Opioid-induced Hyperalgesia.CD59 Regulation by SOX2 Is Required for Epithelial Cancer Stem Cells to Evade Complement Surveillance.Concise review: adult mesenchymal stromal cell therapy for inflammatory diseases: how well are we joining the dots?Regenerative medicine: prospects for the treatment of inflammatory bowel disease.Stromal cells-are they really useful for GVHD?Painting factor H onto mesenchymal stem cells protects the cells from complement- and neutrophil-mediated damage.Modulation of Immune Responses by Mesenchymal Stromal Cells.Concise Review: Innate and Adaptive Immune Recognition of Allogeneic and Xenogeneic Cell Transplants in the Central Nervous System.MSCs: Delivery Routes and Engraftment, Cell-Targeting Strategies, and Immune Modulation.Local Inhibition of Complement Improves Mesenchymal Stem Cell Viability and Function After AdministrationAllogeneic Bone Marrow-Derived Mesenchymal Stromal Cells Expanded In Vitro for Treatment of Aplastic Anemia: A Multicenter Phase II Trial.CD55 regulates self-renewal and cisplatin resistance in endometrioid tumors.Feline foamy virus adversely affects feline mesenchymal stem cell culture and expansion: implications for animal model developmentChallenges and Strategies for Improving the Regenerative Effects of Mesenchymal Stromal Cell-Based Therapies.MALP-2, an agonist of TLR6, promotes the immune status without affecting the differentiation capacity of umbilical cord mesenchymal stem cells.Apoptosis in mesenchymal stromal cells induces in vivo recipient-mediated immunomodulation.Effect of Multiple Intraperitoneal Injections of Human Bone Marrow Mesenchymal Stem Cells on Cuprizone Model of Multiple SclerosisCryopreserved or Fresh Mesenchymal Stromal Cells: Only a Matter of Taste or Key to Unleash the Full Clinical Potential of MSC Therapy?Role of Complement in a Rat Model of Paclitaxel-Induced Peripheral Neuropathy.
P2860
Q26747314-37607FC2-74EA-4E7B-962F-7BDDA6D81BAEQ26782203-77D98F49-23AC-498F-BFC3-FA11448EC311Q26853374-B3D788F8-08F0-4BE7-A221-534DEF8EEC15Q27003371-D73B0CBE-C010-4961-954B-F8892FC10218Q27015774-076CB4D9-E21F-4D65-BA3B-30B887A9CCD6Q28066235-A1E234D3-E747-4443-A246-9553B2EB83EBQ28071840-EE9E2C6D-E16C-4729-BDCC-CDFECDD09A6CQ30488740-C64E6C57-8243-4F47-A553-203E7856D7E5Q30538835-D1EBF102-660A-492E-BEF3-593261599074Q33753368-46FDE381-4FD8-4EC2-87B8-9D226974C6B8Q34653955-28B3D7F2-8086-4502-B83E-0EC8BFC33426Q34803754-8DE03A38-DE08-417B-8D12-F224334350DBQ34920360-939E0063-F122-44F9-8117-C74D8148D227Q35007600-186E4B01-94CB-4A12-A2A9-AE30DB50A9F2Q35078827-02D5DB0C-509F-46AE-8989-9B050D7EBBADQ35186756-F0C1DEB9-FFC5-4358-A670-BE0A404F82F3Q35240062-3B597D71-D40A-4EFA-97E7-47FA5DFC6F58Q35706934-994BB3B4-A960-4DCE-8D76-BFFC83BFA8FCQ36536081-6A51CE8A-E9EF-4E94-9FC5-01E84743A06AQ37020401-3E78FE8E-4E7F-4017-95FF-CCB36E2A93BBQ37117804-EBE62557-3F7D-4B16-8B35-3D3AC6092645Q37198850-30556C72-50D7-478D-A945-F13A40AF43E4Q37583589-66A98165-7EDB-4568-9D0A-5129263B335CQ38114405-9674D321-F147-4000-89EA-AE89DFC2BC25Q38133660-B9F77362-C96B-40E0-9040-C5D9CAA6971AQ38181957-ED8A2585-F560-4FDC-A6F6-6DEEC6D14A24Q38407079-0C44E9F7-91F5-4B30-B77C-7664E219F1DBQ38945318-6C44C5F3-E73B-4F11-95D1-049319E2A409Q39154189-EC0A7938-8B46-443C-8855-735415A90700Q39356606-7C897D3B-168E-4397-A383-276DC88D1CD1Q39633236-CD01C9A7-38E5-4B63-AA77-52941761F23CQ40057019-815C5BBA-2EC8-4D6F-BF9E-EDB772B5A37AQ41611914-899006B4-6C3B-4CB2-8FE7-98C710DBA347Q41657843-36BCCEAA-7026-429A-8A06-BE4E8D26D311Q44298061-B873CDDC-A3CA-4722-8115-8D0D1050E780Q47103685-EE91F054-FF40-459B-9B61-78F3C8000ED1Q47564842-F4C5CFD3-91C4-4D81-BEE7-C735E522EA20Q50058049-FCC56530-0481-4C0D-B86C-BB68DB6A5E88Q50224283-C738EF41-D11B-4603-8E27-E798C5BB2B0AQ52563027-76B1E368-0FC7-42E0-AEC6-EA9AD4935CD8
P2860
Mesenchymal stem cells are injured by complement after their contact with serum
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Mesenchymal stem cells are injured by complement after their contact with serum
@ast
Mesenchymal stem cells are injured by complement after their contact with serum
@en
type
label
Mesenchymal stem cells are injured by complement after their contact with serum
@ast
Mesenchymal stem cells are injured by complement after their contact with serum
@en
prefLabel
Mesenchymal stem cells are injured by complement after their contact with serum
@ast
Mesenchymal stem cells are injured by complement after their contact with serum
@en
P2860
P1433
P1476
Mesenchymal stem cells are injured by complement after their contact with serum
@en
P2860
P304
P356
10.1182/BLOOD-2012-03-420612
P407
P577
2012-09-10T00:00:00Z